Tauriga Sciences, Inc. Logo

Tauriga Sciences, Inc.

TAUG

(1.8)
Stock Price

0,00 USD

-189.64% ROA

0% ROE

-0x PER

Market Cap.

2.999,00 USD

44.79% DER

0% Yield

0% NPM

Tauriga Sciences, Inc. Stock Analysis

Tauriga Sciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Tauriga Sciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (45%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-980.12%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-189.64%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Tauriga Sciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Tauriga Sciences, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Sell
4 Stoch RSI Buy

Tauriga Sciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Tauriga Sciences, Inc. Revenue
Year Revenue Growth
2002 0
2003 13.246 100%
2004 0 0%
2005 120.913 100%
2006 1.132.060 89.32%
2007 196.920 -474.88%
2008 149.507 -31.71%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 96.161 100%
2016 0 0%
2017 0 0%
2018 1.188 100%
2019 57.134 97.92%
2020 234.389 75.62%
2021 285.319 17.85%
2022 410.320 30.46%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Tauriga Sciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 515.279 100%
2011 471.073 -9.38%
2012 820.164 42.56%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 108.942 100%
2018 11.440 -852.29%
2019 13.924 17.84%
2020 6.923 -101.13%
2021 273.385 97.47%
2022 35.124 -678.34%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Tauriga Sciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 2.346.680 100%
2011 1.763.076 -33.1%
2012 5.016.621 64.86%
2013 8.374.216 40.09%
2014 6.142.174 -36.34%
2015 3.882.347 -58.21%
2016 2.027.633 -91.47%
2017 1.432.653 -41.53%
2018 1.944.195 26.31%
2019 1.083.980 -79.36%
2020 1.880.256 42.35%
2021 2.963.739 36.56%
2022 5.001.936 40.75%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Tauriga Sciences, Inc. EBITDA
Year EBITDA Growth
2002 -9.100
2003 -37.841 75.95%
2004 -223.410 83.06%
2005 -1.598.740 86.03%
2006 -2.150.409 25.65%
2007 -1.466.809 -46.6%
2008 -687.272 -113.42%
2009 -334.868 -105.24%
2010 -2.861.959 88.3%
2011 -2.234.149 -28.1%
2012 -6.173.621 63.81%
2013 -11.092.082 44.34%
2014 -9.297.614 -19.3%
2015 -4.890.977 -90.1%
2016 -2.475.865 -97.55%
2017 -1.542.858 -60.47%
2018 256.279 702.02%
2019 -815.888 131.41%
2020 -2.038.096 59.97%
2021 -3.387.737 39.84%
2022 -5.351.588 36.7%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Tauriga Sciences, Inc. Gross Profit
Year Gross Profit Growth
2002 0
2003 6.472 100%
2004 0 0%
2005 -16.676 100%
2006 -541.725 96.92%
2007 -867.164 37.53%
2008 100.265 964.87%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 54.359 100%
2016 0 0%
2017 0 0%
2018 473 100%
2019 20.006 97.64%
2020 37.212 46.24%
2021 122.692 69.67%
2022 224.324 45.31%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Tauriga Sciences, Inc. Net Profit
Year Net Profit Growth
2002 -9.100
2003 -42.696 78.69%
2004 -223.410 80.89%
2005 -1.651.244 86.47%
2006 -2.270.382 27.27%
2007 -1.565.216 -45.05%
2008 -762.059 -105.39%
2009 -334.868 -127.57%
2010 -2.935.831 88.59%
2011 -2.811.538 -4.42%
2012 -6.245.879 54.99%
2013 -11.146.507 43.97%
2014 -9.981.489 -11.67%
2015 -5.088.956 -96.14%
2016 -2.569.153 -98.08%
2017 -2.271.300 -13.11%
2018 -36.127 -6186.99%
2019 -1.097.439 96.71%
2020 -3.935.518 72.11%
2021 -4.719.517 16.61%
2022 -6.437.608 26.69%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Tauriga Sciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -2
2003 -8 87.5%
2004 -1 -700%
2005 -11 90.91%
2006 -16 31.25%
2007 -11 -45.45%
2008 -5 -120%
2009 -2 -400%
2010 -10 90%
2011 -5 -100%
2012 -6 16.67%
2013 -5 -50%
2014 -2 -100%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Tauriga Sciences, Inc. Free Cashflow
Year Free Cashflow Growth
2002 3.434
2003 -11.923 128.8%
2004 -14.768 19.26%
2005 -2.708.545 99.45%
2006 -1.615.972 -67.61%
2007 -798.225 -102.45%
2008 -944.610 15.5%
2009 0 0%
2010 -726.920 100%
2011 -739.354 1.68%
2012 -2.255.876 67.23%
2013 -2.658.323 15.14%
2014 -2.218.299 -19.84%
2015 -1.856.475 -19.49%
2016 -395.536 -369.36%
2017 -652.210 39.35%
2018 256.725 354.05%
2019 -340.975 175.29%
2020 -1.513.174 77.47%
2021 -2.570.672 41.14%
2022 -262.499 -879.31%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Tauriga Sciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
2002 3.434
2003 -11.923 128.8%
2004 -14.768 19.26%
2005 -2.377.695 99.38%
2006 -1.308.317 -81.74%
2007 -795.205 -64.53%
2008 -906.425 12.27%
2009 0 0%
2010 -715.934 100%
2011 -736.909 2.85%
2012 -2.222.296 66.84%
2013 -2.647.490 16.06%
2014 -1.919.415 -37.93%
2015 -1.844.519 -4.06%
2016 -395.536 -366.33%
2017 -651.129 39.25%
2018 259.834 350.59%
2019 -328.585 179.08%
2020 -1.510.562 78.25%
2021 -2.554.578 40.87%
2022 -262.499 -873.18%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Tauriga Sciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
2002 0
2003 0 0%
2004 0 0%
2005 330.850 100%
2006 307.655 -7.54%
2007 3.020 -10087.25%
2008 38.185 92.09%
2009 0 0%
2010 10.986 100%
2011 2.445 -349.33%
2012 33.580 92.72%
2013 10.833 -209.98%
2014 298.884 96.38%
2015 11.956 -2399.87%
2016 0 0%
2017 1.081 100%
2018 3.109 65.23%
2019 12.390 74.91%
2020 2.612 -374.35%
2021 16.094 83.77%
2022 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Tauriga Sciences, Inc. Equity
Year Equity Growth
2002 -10.000
2003 46.946 121.3%
2004 -43.500 207.92%
2005 1.222.768 103.56%
2006 1.960.597 37.63%
2007 525.967 -272.76%
2008 217.724 -141.58%
2009 -111.754 294.82%
2010 -820.739 86.38%
2011 -1.647.965 50.2%
2012 -69.977 -2255.01%
2013 -984.642 92.89%
2014 258.582 480.79%
2015 -1.320.072 119.59%
2016 -2.294.926 42.48%
2017 -2.536.516 9.52%
2018 295.251 959.1%
2019 503.446 41.35%
2020 -308.197 263.35%
2021 1.271.247 124.24%
2022 -745.734 270.47%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Tauriga Sciences, Inc. Assets
Year Assets Growth
2002 20.000
2003 83.576 76.07%
2004 0 0%
2005 4.568.732 100%
2006 3.865.952 -18.18%
2007 2.621.404 -47.48%
2008 2.473.149 -5.99%
2009 0 0%
2010 67.984 100%
2011 17.083 -297.96%
2012 668.356 97.44%
2013 198.856 -236.1%
2014 3.143.874 93.67%
2015 358.641 -776.61%
2016 10.164 -3428.54%
2017 3.794 -167.9%
2018 688.838 99.45%
2019 960.826 28.31%
2020 643.462 -49.32%
2021 2.488.703 74.14%
2022 1.616.661 -53.94%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Tauriga Sciences, Inc. Liabilities
Year Liabilities Growth
2002 30.000
2003 36.630 18.1%
2004 43.500 15.79%
2005 3.345.964 98.7%
2006 1.905.355 -75.61%
2007 2.095.437 9.07%
2008 2.255.425 7.09%
2009 111.754 -1918.21%
2010 888.723 87.43%
2011 1.665.048 46.62%
2012 738.333 -125.51%
2013 1.183.498 37.61%
2014 2.885.292 58.98%
2015 1.678.713 -71.88%
2016 2.305.090 27.17%
2017 2.540.310 9.26%
2018 393.587 -545.43%
2019 457.380 13.95%
2020 951.659 51.94%
2021 1.217.456 21.83%
2022 2.362.395 48.47%

Tauriga Sciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.02
Price to Earning Ratio
-0x
Price To Sales Ratio
0.01x
POCF Ratio
-0
PFCF Ratio
-0
Price to Book Ratio
0
EV to Sales
1.83
EV Over EBITDA
-0.15
EV to Operating CashFlow
-0.2
EV to FreeCashFlow
-0.2
Earnings Yield
-2437.49
FreeCashFlow Yield
-857.18
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.06
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.7
ROE
-9.8
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
10.39
Research & Developement to Revenue
0.96
Stock Based Compensation to Revenue
3.57
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0.01
Capex to Revenue
-0.06
Capex to Depreciation
-9.27
Return on Invested Capital
-2.32
Return on Tangible Assets
-1.9
Days Sales Outstanding
41.23
Days Payables Outstanding
877.44
Days of Inventory on Hand
1452.16
Receivables Turnover
8.85
Payables Turnover
0.42
Inventory Turnover
0.25
Capex per Share
-0

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,01
Tangible Book Value per Share
0.01
Shareholders Equity per Share
0.01
Interest Debt per Share
0.01
Debt to Equity
0.45
Debt to Assets
0.23
Net Debt to EBITDA
-0.15
Current Ratio
2.05
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.45
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
387862
Debt to Market Cap
189.84

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Tauriga Sciences, Inc. Dividends
Year Dividends Growth

Tauriga Sciences, Inc. Profile

About Tauriga Sciences, Inc.

Tauriga Sciences, Inc. produces and sells cannabidiol infused chewing gum under the Tauri-Gum brand name. It also develops anti-nausea products; and skin care products include CBD facemasks; CBD daily moisturizer; CBD anti-wrinkle dream, hand, and foot cream with hemp seed oil; CBD massage and body oil; CBD body revive roll-on; CBD transdermal patch; and CBD body spray. In addition, the company offers rainbow deluxe sampler pack, CBD non-GMO dietary supplements, and CBD scented bath bombs. It sells its products through e-commerce, distributors, and wholesale channels. The company has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 (novel coronavirus) test. Tauriga Sciences, Inc. was founded in 2001 and is headquartered in Wappingers Falls, New York.

CEO
Mr. Seth M. Shaw
Employee
2
Address
4 Nancy Court
Wappingers Falls, 12590

Tauriga Sciences, Inc. Executives & BODs

Tauriga Sciences, Inc. Executives & BODs
# Name Age
1 Mr. Kevin P. Lacey
Chief Financial Officer
70
2 Ms. Adina Miles
Chief Marketing Officer
70
3 Mr. Seth M. Shaw
Chairman & Chief Executive Officer
70

Tauriga Sciences, Inc. Competitors